FDA approves IntelGenx’s Rizafilm for acute migraine treatment
Pharmaceutical Technology
APRIL 18, 2023
IntelGenx Corp announced that the US Food and Drug Administration (FDA) has approved the company’s Rizafilm VersaFilm new drug application (NDA) for the treatment of acute migraine. The drug constricts blood vessels leading to a reduction in swelling and inflammation of blood vessels associated with migraine.
Let's personalize your content